Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  sunitinib malate
Find trials that include:  Any drugs shown
Results 1-21 of 21 for your search:
Start Over
Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: AGS-003-007, NCI-2013-00717, 2012-000871-17, NCT01582672
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CA209-214, NCI-2014-01993, 2014-001750-42, NCT02231749
A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CDX1127-04, NCI-2015-00740, NCT02386111
Sunitinib Malate in Treating Patients With Stage III or Stage IV Mucosal or Acral Lentiginous Melanoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 06-145, NCI-2010-00061, NCT00577382
BCG Intravesical Solution and Sunitinib Malate in Treating Patients With Bladder Cancer
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: UMCC 2008.086, NCI-2011-03616, NCT00794950
Everolimus or Sunitinib Malate in Treating Patients With Metastatic Non-Clear Cell Kidney Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: Pro00020714, NCI-2013-02190, NCT01108445
Sunitinib Malate with or without Gemcitabine Hydrochloride in Treating Patients with Advanced Kidney Cancer That Cannot Be Removed by Surgery
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: E1808, NCI-2011-02055, CDR0000681614, ECOG-E1808, NCT01164228
Targeted Enzyme Inhibitor Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Thymic Malignancies
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-C-0096, NCI-2013-01478, 110096, P10782, 8639, NCT01306045
Sunitinib Malate or Cediranib Maleate in Treating Patients with Metastatic Soft Tissue Sarcoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 16 to 20
Trial IDs: 11-C-0200, NCI-2013-01496, 110200, P11836, P8875_A21PAMDREVW01, 8875, NCT01391962
A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 to 21
Trial IDs: A6181196, NCI-2014-00205, 2011-002008-33, NCT01396148
Alternating Sunitinib Malate and Temsirolimus Therapy in Treating Patients With Metastatic Kidney Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: D1011, NCI-2011-03505, NCT01517243
Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 to 69
Trial IDs: 7195, NCI-2012-01084, CA180-392, NCT01620216
Trebananib with or without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients with Advanced Kidney Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PHII-122, NCI-2012-01289, CDR0000738785, 9048, NCT01664182
Sunitinib Malate in Treating Patients with Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Never Smoked
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-086, NCI-2013-01116, NCT01829217
Sunitinib Malate on an Alternative Schedule in Treating in Patients with Metastatic Kidney Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2013-0944, NCI-2014-01908, NCI-2014-01171, NCT02060370
CRLX101 in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CRLX101-208, NCI-2014-02343, NCT02187302
Mutation-Targeted Therapy with Sunitinib Malate or Everolimus in Treating Patients with Advanced Neuroendocrine Tumors of the Gastrointestinal Tract or Pancreas
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 15-C-0040, NCI-2015-00091, 14-C-0000, 150040, 339636, P141605, NCT02315625
A Rollover Protocol for Subjects Previously Treated With AGS-003
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: AGS-003-005, NCI-2011-03808, NCT01482949
Start Over